The expansion will grow domestic capacity across four sites and support the production of more than 12 billion doses of ...

Shares of Hikma Pharmaceuticals PLC HIK slid 1.18% to £20.04 Friday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.20% to 9,120.31 ...

So let's assess the underlying fundamentals over the last 3 years and see if they've moved in lock-step with shareholder returns. This technology could replace computers: discover the 20 stocks are ...

Hikma Pharmaceuticals PLC HIK shares rallied 1.73% to £21.12 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.69% to ...

In the last 15 years, Hikma has asserted itself as one of the U.S.’ top three sterile injectable suppliers by volume, Bill Larkins, Ph.D., president of Hikma Injectables, said in a statement.

Hikma Pharmaceuticals USA (HKMPF) plans to invest $1 billion through 2030 to boost its U.S. manufacturing and R&D. Read more details here.

(RTTNews) - Hikma Pharmaceuticals Plc (HIK, HIK.L), on Thursday, reiterated its full-year guidance following a solid start to 2025, highlighting strong performance across its core business segments.